{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:29:49Z","timestamp":1786483789213,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lfs.2026.124591","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:09:59Z","timestamp":1783699799000},"page":"124591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Letter to the editor regarding conflicting reports of opaganib efficacy against high-fat diet-induced obesity"],"prefix":"10.1016","volume":"402","author":[{"given":"Charles D.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn W.","family":"Maines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2026.124591_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123952","article-title":"Subcutaneous administration of the sphingosine kinase 2 inhibitor ABC294640 has no metabolic benefits in high fat diet-induced obesity in male mice","volume":"380","author":"Skoug","year":"2025","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2026.124591_bb0010","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2147\/DMSO.S514548","article-title":"Opaganib promotes weight loss and suppresses high-fat diet-induced obesity and glucose intolerance","volume":"18","author":"Maines","year":"2025","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.lfs.2026.124591_bb0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.109.163444","article-title":"Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2","volume":"333","author":"French","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2026.124591_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fasebj.2020.34.s1.04663","article-title":"Therapeutic inhibition of sphingosine kinase SphK2 lowers blood pressure levels in an experimental model of hypertension by reducing CD4+ T-cell responses","volume":"34","author":"Don-Doncow","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.lfs.2026.124591_bb0025","first-page":"1","article-title":"European Society for Microcirculation Conference 2023","volume":"60","year":"2023","journal-title":"J. Vasc. Res."},{"key":"10.1016\/j.lfs.2026.124591_bb0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/cvr\/cvw256","article-title":"Sphingosine-1-phosphate signalling-a key player in the pathogenesis of Angiotensin II-induced hypertension","volume":"113","author":"Meissner","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2026.124591_bb0035","series-title":"Submitted for publication","article-title":"Opaganib protects against high-fat diet-induced hypercholesterolemia and non-alchoholic fatty liver disease","author":"Maines","year":"2026"},{"key":"10.1016\/j.lfs.2026.124591_bb0040","article-title":"Characterization of isoenzyme-selective inhibitors of human sphingosine kinases","volume":"7","author":"Gao","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2026.124591_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113191","article-title":"Opaganib protects against radiation toxicity: implications for homeland security and antitumor radiotherapy","volume":"23","author":"Maines","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124591_bb0050","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1007\/s00296-012-2493-2","article-title":"Impact of sphingosine kinase 2 deficiency on the development of TNF-alpha-induced inflammatory arthritis","volume":"33","author":"Baker","year":"2013","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.lfs.2026.124591_bb0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10787-010-0060-6","article-title":"Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase","volume":"19","author":"Fitzpatrick","year":"2011","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.lfs.2026.124591_bb0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000323911","article-title":"Experimental osteoarthritis in rats is attenuated by ABC294640, a selective inhibitor of sphingosine kinase-2","volume":"87","author":"Fitzpatrick","year":"2011","journal-title":"Pharmacology"},{"key":"10.1016\/j.lfs.2026.124591_bb0065","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1160\/TH11-08-0583","article-title":"Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(\u2212\/\u2212)) mice","volume":"107","author":"Poti","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.lfs.2026.124591_bb0070","article-title":"SPHK inhibitors and zoledronic acid suppress osteoclastogenesis and wear particle-induced osteolysis","volume":"12","author":"Gu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124591_bb0075","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/carcin\/bgq158","article-title":"Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase","volume":"31","author":"Chumanevich","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.lfs.2026.124591_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00631","article-title":"Targeting sphingosine kinase isoforms effectively reduces growth and survival of neoplastic mast cells with D816V-KIT","volume":"9","author":"Bandara","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124591_bb0085","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.2147\/OTT.S208519","article-title":"Sphingosine kinase 2 inhibitor ABC294640 displays anti-epithelial ovarian cancer activities in vitro and in vivo","volume":"12","author":"Song","year":"2019","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.lfs.2026.124591_bb0090","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1535-7163.MCT-15-0279","article-title":"The sphingosine kinase 2 inhibitor ABC294640 reduces the growth of prostate cancer cells and results in accumulation of dihydroceramides in vitro and in vivo","volume":"14","author":"Venant","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lfs.2026.124591_bb0095","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/blood-2014-03-559385","article-title":"Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma","volume":"124","author":"Venkata","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2026.124591_bb0100","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1258\/ebm.2012.012028","article-title":"Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer","volume":"237","author":"Antoon","year":"2012","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.lfs.2026.124591_bb0105","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4161\/cbt.11.7.14903","article-title":"Targeting NFkB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2","volume":"11","author":"Antoon","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.lfs.2026.124591_bb0110","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1158\/0008-5472.CAN-13-2732","article-title":"Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression","volume":"74","author":"Wallington-Beddoe","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2026.124591_bb0115","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00109-024-02456-2","article-title":"Sphingosine is involved in PAPTP-induced death of pancreas cancer cells by interfering with mitochondrial functions","volume":"102","author":"Patel","year":"2024","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.lfs.2026.124591_bb0120","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1002\/ijc.31234","article-title":"The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo","volume":"142","author":"Dai","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lfs.2026.124591_bb0125","doi-asserted-by":"crossref","first-page":"744","DOI":"10.14740\/wjon1890","article-title":"Targeting SNAI1-mediated colorectal cancer chemoresistance and stemness by sphingosine kinase 2 inhibition","volume":"15","author":"Janakiraman","year":"2024","journal-title":"World. J. Oncol."},{"key":"10.1016\/j.lfs.2026.124591_bb0130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.14740\/wjon1768","article-title":"Sphingosine-1-phosphate inhibition increases endoplasmic reticulum stress to enhance oxaliplatin sensitivity in pancreatic cancer","volume":"15","author":"Gao","year":"2024","journal-title":"World. J. Oncol."},{"key":"10.1016\/j.lfs.2026.124591_bb0135","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1210\/en.2010-0420","article-title":"Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640","volume":"151","author":"Antoon","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.lfs.2026.124591_bb0140","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/1535-7163.MCT-13-0466","article-title":"Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma","volume":"13","author":"Qin","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lfs.2026.124591_bb0145","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-015-0205-y","article-title":"Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo","volume":"34","author":"Xun","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2026.124591_bb0150","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.23415","article-title":"The sphingosine kinase 2 inhibitor ABC294640 inhibits cervical carcinoma cell growth","volume":"9","author":"Xu","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2026.124591_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00694","article-title":"Targeting SphK2 reverses acquired resistance of regorafenib in hepatocellular carcinoma","volume":"10","author":"Shi","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2026.124591_bb0160","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/jpet.109.163337","article-title":"A novel sphingosine kinase inhibitor induces autophagy in tumor cells","volume":"333","author":"Beljanski","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2026.124591_bb0165","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4161\/cbt.11.5.14677","article-title":"Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts","volume":"11","author":"Beljanski","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.lfs.2026.124591_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16091779","article-title":"Opaganib downregulates N-Myc expression and suppresses in vitro and in vivo growth of neuroblastoma cells","volume":"16","author":"Maines","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2026.124591_bb0175","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/1541-7786.MCR-14-0626","article-title":"Downregulation of critical oncogenes by the selective SK2 inhibitor ABC294640 hinders prostate cancer progression","volume":"13","author":"Schrecengost","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.lfs.2026.124591_bb0180","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1002\/cam4.1543","article-title":"The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation","volume":"7","author":"Sundaramoorthy","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.lfs.2026.124591_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16051050","article-title":"Combined antitumor effect of the serine protease urokinase inhibitor upamostat and the sphingosine kinase 2 inhibitor opaganib on cholangiocarcinoma patient-derived xenografts","volume":"16","author":"Asumda","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2026.124591_bb0190","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s10637-010-9452-0","article-title":"Combined anticancer effects of sphingosine kinase inhibitors and sorafenib","volume":"29","author":"Beljanski","year":"2011","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.lfs.2026.124591_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316901","article-title":"Opaganib (ABC294640) induces immunogenic tumor cell death and enhances checkpoint antibody therapy","volume":"24","author":"Maines","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124591_bb0200","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaa4998","article-title":"Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation","volume":"8","author":"Panneer Selvam","year":"2015","journal-title":"Sci. Signal."},{"key":"10.1016\/j.lfs.2026.124591_bb0205","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1158\/1535-7163.MCT-17-0485","article-title":"ABC294640, a novel sphingosine kinase 2 inhibitor, induces oncogenic virus-infected cell autophagic death and represses tumor growth","volume":"16","author":"Dai","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lfs.2026.124591_bb0210","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1167\/iovs.05-1236","article-title":"Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases","volume":"47","author":"Maines","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.lfs.2026.124591_bb0215","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10787-010-0032-x","article-title":"Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease","volume":"18","author":"Maines","year":"2010","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.lfs.2026.124591_bb0220","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s10620-007-0133-6","article-title":"Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase","volume":"53","author":"Maines","year":"2008","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.lfs.2026.124591_bb0225","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.antiviral.2018.08.010","article-title":"Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice","volume":"158","author":"Xia","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.lfs.2026.124591_bb0230","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1016\/j.bbadis.2018.09.007","article-title":"Sphingosine kinase 2 cooperating with Fyn promotes kidney fibroblast activation and fibrosis via STAT3 and AKT","volume":"1864","author":"Zhu","year":"2018","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.lfs.2026.124591_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25042322","article-title":"The sphingolipid-modulating drug opaganib protects against radiation-induced lung inflammation and fibrosis: potential uses as a medical countermeasure and in cancer radiotherapy","volume":"25","author":"Maines","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124591_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053521","article-title":"Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis","volume":"8","author":"Snider","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2026.124591_bb0245","article-title":"Sphingosine kinase 2 inhibition ameliorates neuroinflammation in diet-induced obese mice","author":"Vanherle","year":"2025","journal-title":"Aging Dis."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526004005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526004005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:51:14Z","timestamp":1786481474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320526004005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":49,"alternative-id":["S0024320526004005"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124591","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter to the editor regarding conflicting reports of opaganib efficacy against high-fat diet-induced obesity","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124592","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2025.123952","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124591"}}